Pharmacology of Combined Mesalzine and Rifaximin Therapy for Inflammatory Bowel Disease

  • Posted on: 30 April 2016
  • By: admin

 

Magazine Home


May 2016 ARTICLE LIST >>

PharmaTutor (May- 2016)

 

Print-ISSN: 2394 - 6679
e-ISSN: 2347 - 7881
(Volume 4, Issue 5)

 

Received On: 04/01/2016; Accepted On: 21/01/2016; Published On: 01/05/2016

 

AUTHORS:
Prajapati Krishna V*, Raj Hasumati A, Jain Vinit C, Prajapati Neelam S.
Department of Quality Assurance,
Shree Dhanvantary Pharmacy College, Kim, Surat
* krish1112k@gmail.com

 

ABSTRACT: This review article presents the pharmacology of combined Mesalazine and Rifaximin therapy especially in inflammatory bowel disease. Mesalazine is Used as in anti-inflammatory agent, Non-Steroidal. Rifaximin is used in Gastrointestinal Agents, Anti-infective agent. The use of Rifaximin in combination with Mesalazine has been proved to provide beneficial effect in inflammatory bowel disease. The mechanism of Mesalazine and Rifaximin is quite different. Mesalamine and Rifaximin are two different types of drugs offering some symptomatic relief to the IBD patients. Mesalamine treats inflammation, whereas, Rifaximin reduces bio burden. Patent for combination of both drugs were approved by WIPO. The main objective of this review article is to provide pharmacological information of combined therapy of Mesalazine and Rifaximin to researcher in development of combined dosage form of this.

 

How to cite this article: Prajapati KV, Raj HA, Jain VC, Prajapati NS; Pharmacology of Combined Mesalzine and Rifaximin Therapy for Inflammatory Bowel Disease; PharmaTutor; 2016; 4(5); 41-45

 

[ABSTRACT WITH CITATION]   [VIEW AS HTML